Other

OCI Unrealized Holding Gain (Loss) on Securities, Net of Tax

Year-over-year, this metric declined by 454.6%, from $1.03M to -$3.65M. Over 3 years (FY 2021 to FY 2025), OCI Unrealized Holding Gain (Loss) on Securities, Net of Tax shows an upward trend with a -2.8% CAGR.

Analysis

StatementIncome Statement
SectionOther
First reportedQ1 2013
Last reportedQ1 2026Apr 30, 2026
Metric ID: cop_oci_unrealized_holding_gain_loss_on_securities_net_of_tax

Historical Data

19 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value-$247.00K-$64.00K-$1.67M-$7.22M-$1.73M-$2.05M$4.13M-$2.03M$1.88M$7.04M-$3.57M-$727.00K$9.08M-$4.79M$1.03M-$343.00K$1.13M$0.00-$3.65M
QoQ Change—+74.1%<-999%-333.2%+76.0%-18.4%+300.9%-149.1%+192.7%+274.9%-150.7%+79.6%>999%-152.7%+121.5%-133.3%+429.7%-100.0%—
YoY Change————-602.0%<-999%+157.2%-16.8%+191.5%—-186.5%+64.1%+383.4%-168.0%+128.9%+52.8%-87.5%+100.0%-454.6%
Range-$7.22M – $9.08M
CAGR+82.0%
Avg YoY Growth-253.2%
Median YoY Growth+18.0%
Current Streak2 quarters decline

Frequently Asked Questions

What is Alnylam Pharmaceuticals's oci unrealized holding gain (loss) on securities, net of tax?
Alnylam Pharmaceuticals (ALNY) reported oci unrealized holding gain (loss) on securities, net of tax of -$3.65M in Q1 2026.
How has Alnylam Pharmaceuticals's oci unrealized holding gain (loss) on securities, net of tax changed year-over-year?
Alnylam Pharmaceuticals's oci unrealized holding gain (loss) on securities, net of tax decreased by 454.6% year-over-year, from $1.03M to -$3.65M.
What is the long-term trend for Alnylam Pharmaceuticals's oci unrealized holding gain (loss) on securities, net of tax?
Over 3 years (2021 to 2025), Alnylam Pharmaceuticals's oci unrealized holding gain (loss) on securities, net of tax has grown at a -2.8% compound annual growth rate (CAGR), from -$1.98M to $1.82M.